Targeted cancer therapy: the initial high concentration may slow down the selection for resistance
Aging · 2024
DOI: 10.18632/aging.206046 ↗Kurz gefasst
Editorial in der Zeitschrift Aging, 2024. Verfasst von Mikhail V Blagosklonny. Beteiligte Einrichtung: Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Neoplasms, Antineoplastic Agents, Molecular Targeted Therapy. Die Arbeit nennt 2 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Unfortunately, any targeted therapy is, always, started with low levels of the drug in the organism, selecting for drug resistance. One should propose that initial drug levels must be maximized, and durations may be minimized, ideally, as portions of preemptive combination of targeted drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Zitieren
APA
Blagosklonny, M. V. (2024). Targeted cancer therapy: the initial high concentration may slow down the selection for resistance. Aging. https://doi.org/10.18632/aging.206046
Vancouver
Blagosklonny MV. Targeted cancer therapy: the initial high concentration may slow down the selection for resistance. Aging. 2024. doi:10.18632/aging.206046
BibTeX
@article{Blagosklonny2024,
author = {Blagosklonny, Mikhail V},
title = {Targeted cancer therapy: the initial high concentration may slow down the selection for resistance},
journal = {Aging},
year = {2024},
doi = {10.18632/aging.206046}
}
EUVIMED